Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Medscape
medscape.com > viewarticle > cancer-pain-remains-major-clinical-challenge-2026a1000x7k

Cancer Pain Remains a Major Clinical Challenge

6+ day, 10+ hour ago   (822+ words) “Pain remains a very common issue among cancer patients; its prevalence continues to be very high,” lamented María Luz Cánovas Martínez, head of the pain unit and the Department of Anesthesiology and Resuscitation at the Ourense University Hospital Complex, Ourense,…...

The Marijuana Herald
themarijuanaherald.com > 2026 > 09 > thc-breast-cancer

Study Finds Low-Dose THC Reduces Breast Cancer Aggressiveness, Improves Tamoxifen Sensitivity in Tumor Models

1+ week, 5+ day ago   (448+ words) Montana Implements New Marijuana Labeling, Tracking and Recall Rules A new study finds that brief exposure to low doses of THC can push breast cancer cells toward a less aggressive state, reducing their ability to invade, self-renew and initiate new…...

ScienceDaily
sciencedaily.com > releases > 2026 > 08 > 260828082330.htm

A cancer therapy put severe rheumatoid arthritis into remission

2+ week, 1+ day ago   (1055+ words) Immunotherapies such as CAR T-cell therapy were originally developed mainly to fight cancer. But scientists are now investigating whether these personalized treatments, made from a patient's own immune cells, could also help treat or even potentially cure autoimmune diseases. Why…...

ScienceAlert
sciencealert.com > scientists-discover-a-cannabis-receptor-that-could-stop-breast-cancer-spreading

Scientists Discover a Cannabis Receptor That Could Stop Breast Cancer Spreading

2+ week, 1+ day ago   (614+ words) Cancer cells are proving trickier than we thought, so scientists are getting even trickier to shift the survival odds in our favor. Recent medical research has highlighted a significant issue: cancer cells display plasticity. Some cancer cells can spontaneously revert…...

@PRNewswire
prnewswire.com > news-releases > vascarta-outlines-vas-101s-vasceptor-potential-as-a-non-opioid-advance-in-pain-medicine-across-sickle-cell-disease-osteoarthritis-and-cancer-302858963.html

Vascarta Outlines VAS-101's (Vasceptor®) Potential as a Non-Opioid Advance in Pain Medicine Across Sickle Cell Disease, Osteoarthritis, and Cancer

2+ week, 6+ day ago   (157+ words) Aug 25, 2026, 07:45 ET A Common Pathway Behind Very Different Pains Vasceptor is built on Vascarta's patented Vasporta™ gel-based delivery platform, which, combined with a small-molecule active pharmaceutical ingredient such as curcumin, is designed to cross the skin and reach plasma and…...

University of Toronto
temertymedicine.utoronto.ca > event > epic-symposium-2026

EPIC Symposium 2026 | Temerty Faculty of Medicine

3+ week, 3+ day ago   (141+ words) EPIC Symposium 2026 University of Toronto We're excited to announce that registration for the 2026 EPIC Symposium is now open. Following the numerous infectious outbreaks we've all be tracking this year — from hantavirus and Ebola to cyclosporiasis and measles — the theme for…...

StudyFinds
studyfinds.com > old-arthritis-drug-could-fix-cancer-immunotherapys-scariest-side-effect

Old Arthritis Drug Could Fix Cancer Immunotherapy's Scariest Side Effect

3+ week, 4+ day ago   (424+ words) Home › Drug & Medication News Reviewed by Patrisha Antonaros Research led by Erin A. Dean (University of California, Irvine) CAR T-cell therapy works by genetically re-engineering a patient’s own immune cells to find and destroy cancer. It has produced remarkable results…...

BiotechDispatch
biotechdispatch.com.au > news > mesoblast-completes-treatment-in-pivotal-low-back-pain-trial-as-phase-3-readout-approaches

Mesoblast completes treatment in pivotal low back pain trial as phase 3 readout approaches

3+ week, 6+ day ago   (340+ words) Mesoblast has completed treatment of all 350 patients in its pivotal phase 3 trial of rexlemestrocel-L for chronic low back pain caused by inflammatory degenerative disc disease, putting the company on track for top-line results in mid-2027. The trial, known as MSB-DR004, is…...